Arctic Bioscience AS reported that the company has now recruited more than 75% of the patients required for the trial. The HeROPA phase IIb clinical trial of HRO350 - a novel, oral drug candidate for the treatment of mild-to-moderate psoriasis - is ongoing in 5 countries in Europe; UK, Germany, Poland, Finland and Norway. As planned, recruitment speed has increased throughout fall as new clinics have been activated.

Recruitment is going particularly well in Germany and Poland. A total of 519 patients are to be included in the trial. To date, more than 75% of the needed patients have been recruited.